Biogen Aktie
159,09USD | -1,82USD | -1,13% |
WKN: 789617 / ISIN: US09062X1037
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,29 |
The Vanguard Group, Inc. | 11,45 |
PRIMECAP Management Co. | 11,20 |
PRIMECAP Management Co. | 11,17 |
Vanguard Group, Inc. (Subfiler) | 11,01 |
Vanguard PRIMECAP Fund | 6,30 |
SSgA Funds Management, Inc. | 5,04 |
State Street Corp. | 5,04 |
BlackRock Fund Advisors | 3,53 |
Wellington Management Co. LLP (Wellington Breakout) | 3,43 |
Vanguard Total Stock Market ETF | 3,16 |
Vanguard Health Care Fund | 3,13 |
T. Rowe Price Investment Management, Inc. | 2,92 |
Vanguard 500 Index Fund | 2,65 |
Geode Capital Management LLC | 2,48 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 7 400 | 9 100 | 9 610 | 8 725 | 7 570 |
Umsatz pro Mitarbeiter in Mio. EUR | 1,72 | 1,36 | 1,08 | 1,08 | 1,24 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 8 382 | 6 887 | 7 857 | 9 791 | 6 859 |
Summe Anlagevermögen | 18 853 | 17 732 | 16 021 | 14 763 | 19 986 |
Summe Aktiva | 27 234 | 24 619 | 23 877 | 24 554 | 26 845 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 13 895 | 13 933 | 12 918 | 11 166 | 12 045 |
Summe Eigenkapital | 13 339 | 10 686 | 10 960 | 13 388 | 14 799 |
Summe Passiva | 27 234 | 24 619 | 23 877 | 24 554 | 26 845 |
Adresse
225 Binney Street, 02142 Cambridge | |
Telefon | +1 (617) 679-2000 |
Internet | http://www.biogen.com |
Management
Adam Keeney
Executive VP & Head-Corporate Development |
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences |
Caroline D. Dorsa
Chairman |
Christopher A. Viehbacher
President, Chief Executive Officer & Director |
Chuck Triano
Head-Investor Relations |
Daniel Quirk
Chief Medical Officer & Head-Medical Affairs |
Eric K. Rowinsky
Independent Director |
Ginger Gregory
Chief Human Resources Officer & Executive VP |
Jake Elkins
Vice President & Head-Acute Neurology Research |
Jane Grogan
Executive Vice President & Head-Research |
Jesus B. Mantas
Independent Director |
Lloyd B. Minor
Director |
Maria C. Freire
Independent Director |
Menelas NICOLAS Pangalos
Director |
Michael E. Dambach
Treasurer & Vice President |
Michael Hencke
Executive Director-Investor Relations |
Michael R. McDonnell
Chief Financial Officer & Executive Vice President |
Monish Patolawala
Independent Director |
Nancy A. Simonian
Vice President-Medical Research & Development |
Nicole Murphy
Head-Pharmaceutical Operations & Technology |
Priya Singhal
Head-Development |
Rachid Izzar
Executive Vice President |
Robert Kilo
Account Director |
Robin C. Kramer
Chief Accounting Officer & Senior Vice President |
Stephen A. Sherwin
Independent Director |
Susan H. Alexander
Chief Legal Officer & Executive Vice President |
Susan Langer
Independent Director |
Tom Holmes
Senior Director-External Manufacturing |
Wendell C. Taylor
Secretary & Chief Counsel |
William A. Hawkins
Independent Director |
Xu Cheryl
Vice President-Public Policy & Government Affairs |